Key result
Deregulation of RGS2 leads to exacerbated G alphaq/11 signaling, contributing to the pathogenesis of hypertension, cardiac hypertrophy, and heart failure.
Design
Review
Loading...
May position RGS2 as therapeutic target in hypertension and HF; leaves open clinical validation from current evidence.
RGS2 is a critical endogenous regulator of Galphaq/11 signaling, and its deregulation plays a key role in the pathogenesis of hypertension and hypertensive heart disease, making it a potential therapeutic target.
A 2009 study conducted a review in Cardiovascular diseases (hypertension, cardiac hypertrophy, heart failure). RGS2 deregulation was evaluated. Deregulation of RGS2 leads to exacerbated G alphaq/11 signaling, contributing to the pathogenesis of hypertension, cardiac hypertrophy, and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: